Who Paid My Doc
Roctavian
Drug Hemophilia A
NDC 68135-927-48
General payments
$287,162
Research payments
$1,561,096
Through program year 2025, $287,162 in general payments and $1,561,096 in research payments were reported against Roctavian (Hemophilia A).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $36,417 | 62 |
| 2025 | Research | $312,952 | 94 |
| 2024 | General | $215,822 | 274 |
| 2024 | Research | $873,245 | 171 |
| 2023 | General | $34,923 | 74 |
| 2023 | Research | $374,898 | 98 |
Breakdown
The top 5 of 41 recipients; each share is of general payments naming this product in 2025.
The top 5 of 7 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 18 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
410 general · 363 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.